Indications for Intestinal Transplantation.


Journal

Gastroenterology clinics of North America
ISSN: 1558-1942
Titre abrégé: Gastroenterol Clin North Am
Pays: United States
ID NLM: 8706257

Informations de publication

Date de publication:
Jun 2024
Historique:
medline: 9 5 2024
pubmed: 9 5 2024
entrez: 8 5 2024
Statut: ppublish

Résumé

Outcomes for patients with chronic intestinal failure have improved with organization of experts into multidisciplinary teams delivering care in intestinal rehabilitation programs. There have been improvements in understanding of intestinal failure complications as well as development of newer therapies that have amplified the improvements in survival. In spite of this encouraging trend, patients who fail PN are often referred too late for intestinal transplantation. The author proposes a more rational framework that might allow earlier identification of intestinal failure patients at risk for PN-failure, who could appropriately be considered earlier for intestinal transplantation with improvements in overall outcomes.

Identifiants

pubmed: 38719375
pii: S0889-8553(24)00009-8
doi: 10.1016/j.gtc.2024.02.001
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

233-244

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure K.R. Iyer is a Scientific advisor and Consultant at Ironwood Pharmaceuticals and a Scientific advisor at Northsea Therapeutics and Hanmi Pharmaceuticals. K.R. Iyer received Grant support from Ironwood Pharmaceuticals, Takeda Pharmaceuticals, Northsea Therapeutics, and Hanmi Pharmaceuticals.

Auteurs

Kishore R Iyer (KR)

Intestinal Rehabilitation & Transplant Program, Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital, One Gustave Levy Place, Box 1104, New York 10029, USA. Electronic address: kishore.iyer@mountsinai.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH